Associate Professor Aaron Sverdlov
Director of Heart Failure
School of Medicine and Public Health
- Email:aaron.sverdlov@newcastle.edu.au
- Phone:(02) 4042 0725
Career Summary
Biography
Associate Professor Aaron Sverdlov is a cardiologist and clinician-scientist with proven track record in basic through to clinical research. His research interests encompass a broad spectrum of topics related to heart failure and cardio-oncology (cardiovascular complications of cancer therapies).
Personal statement
I am committed to improving management and outcomes for patients with heart failure through better understanding of mechanisms involved and discovering novel biomarkers and therapies.
Biography
Dr Sverdlov received his medical degree (MBBS) from the University of Adelaide, Australia in 2000. Then he completed his post-graduate training in general medicine and cardiology, including serving as a Chief Medical Resident for 2 years. He was admitted to the Fellowship of the Royal Australasian College of Physicians (FRACP) in December 2007, and then appointed staff specialist in cardiology at the Queen Elizabeth Hospital and Lyell McEwin Hospital from February 2008.
Aaron Sverdlov was awarded his PhD in 2012 from the University of Adelaide under supervision of Prof John Horowitz. His doctoral work was on pathogenesis of aortic valve disease: Aaron led the aortic valve stenosis group at the Queen Elizabeth Hospital and provided the first evidence in humans that progression of aortic stenosis is amenable to treatment with renin-angiotensin-aldosterone system inhibitors. He was then awarded an NHMRC CJ Martin Fellowship, and later AHA Postdoctoral Fellowship to undertake postdoctoral work with Prof WS Colucci at Boston University (2012-15). There he studied mechanisms regulating cardiac function and energetics in models of obesity-induced heart disease. He proved that mitochondrial ROS play a key pathogenic role in metabolic heart disease and identified novel reactive cysteines in mitochondrial complex II that modulate its function and lead to cardiac energetic impairment. He was also involved in describing a new method for quantitation of FDG PET/CT in cardiac sarcoidosis: this work has been heavily cited and this method has been adopted by a number of institutions. Aaron's postdoctoral work gained him a reputation as an expert and leader in mitochondrial redox field.
Upon return to Australia in 2015, in partnership with his wife, A/Prof Doan Ngo, he established and co-led Cardiometabolic research group as part of the Cardiovascular Program led by Prof John Horowitz at the Basil Hetzel Institute.
Aaron relocated to Newcastle in 2017 where he was appointed Associate Professor and Director of Heart Failure at the University of Newcastle. He has a Clinical Academic appointment as a cardiologist at the John Hunter Hospital and is a Clinical Lead of Heart Failure Services for Hunter New England Local Health District.
Aaron has been awarded 4-year Heart Foundation Future Leader Fellowship for his research program "Bench-to-bedside approach to improving management and outcomes for patients with heart failure" commencing in January 2018.
Together with A/Prof Doan Ngo, Aaron has established the first-in-Australia bench-to-bedside "Cancer and the Heart" cardio-oncology program combining basic and clinical research into cancer therapy-related cardiotoxicity with Calvary Mater Newcastle Hospital-based clinical outpatient service. This program is a collaboration between Cancer Network, Cardiology, Oncology, Haematology and Radiation oncology departments and is supported by the grants from the Heart Foundation of Australia and NSW Ministry of Health.
In November 2018, Aaron was a recipient of a Ministerial Award for Rising Stars in Cardiovascular Research.
Research Expertise
Aaron Sverdlov's research encompasses a full spectrum of translation from bench to bedside and service delivery. He has a basic and translational lab at the Hunter Medical Research Institute and shares a research lab with A/Prof Doan Ngo on the Callaghan Campus. His clinical research is at the John Hunter Hospital, Calvary Mater Newcastle and other sites across the Health District.
Broad goals of Aaron's research program are to improve care and health outcomes for patients with heart disease through better understanding of mechanisms responsible for development of heart failure, prevention and early detection of heart disease through development of novel biomarkers and improved delivery of healthcare by dedicated and integrated multidisciplinary approach.
Aaron's specific research interests directions are:
- mechanisms underlying development of heart failure, especially heart failure due to obesity and diabetes
- role of mitochondria and redox stress in heart failure
- mechanisms of development of cancer therapy-mediated cardiotoxicity
- role of novel biomarkers in early detection of various forms of heart disease
- basic and clinical factors reponsible for development and progression of aortic valve disease
- development and evaluation of integrated multidisciplinary heart failure service incorporating research and innovation
- development and evaluation of cardio-oncology clinical and translational program
- evaluation of new treatment options for patients with obesity, heart failure and chemotherapy-induced cardiotoxicity
Across these projects Aaron has a number of local, national and international collaborators.
Track record, peer review and service to the field
Aaron has over 50 career (since 2008) peer-reviewed publications and 4 book chapters (including chapters on Oxidative Stress in Heart Failure in the textbook “Heart Failure: A Companion to Braunwald’s Heart Disease”) with over 1100 citations and has had more than 80 presentations at international and national meetings. He received over 30 competitive grants, with >20 in the last 5 years (total >$2.5M AUD).
Aaron Sverdlov serves on the NHMRC's ECF Biomedical Panel (2015-6), NHMRC Cardiovascular Diseases GRP (2016-7) and NHMRC Ideas Grant Panel (2019); Heart Foundation of Australia Future Leader Fellowship (2019) and Postdoctoral Fellowships Committees (2017-8); Hunter New England Local Health District TRGS EOI review panel (2017); American Heart Association Cardiac Biology Program Peer Review Committee (2017-9) and Rebecca Cooper Medical Research Foundation grant advisory panel (2016).
He is also a reviewer for the European Society of Cardiology (ESC), Australian Research Council (ARC), Cardiac Society of Australia and New Zealand (CSANZ), Medical Research Council (UK), Croatian Science Foundation, Diabetes Australia, Medical Research Council UK (MRC), Singapore Ministry of Health and Society for Redox Biology and Medicine (SFRBM).
Aaron is an Associate Editor for Heart Lung and Circulation and is on editorial board of Hypertension, Frontiers in Cardiovascular Medicine and Reactive Oxygen Species. He is a regular reviewer for multiple leading cardiovascular, pharmacology and basic science journals including Circulation Research, JACC, Hypertension, JMCC, International Journal of Cardiology, Antioxidant Redox Signaling, Cardiovascular Therapeutics and British Journal of Pharmacology.
Teaching and Education
Aaron has been involved in undergraduate teaching in medicine at the University of Newcastle and University of Adelaide as well as Boston University, USA. He supervised numerous clinical students and physician trainees especially in his capacity as the Chief Medical Resident. As a postdoctoral fellow at the Boston University he supervised and mentored honours, PhD and MD/PhD students. Currently he co-supervises 6 PhD, 4 honours students and 1 postdoctoral fellow across University of Newcastle, University of Adelaide and Flinders University of SA. He is involved in professional education of general practitioners and physicians in community and hospital settings.
Collaborations
In addition to multiple collaborations within University of Newcastle, HMRI and Hunter New England Local Health District, Aaron has active research collaborations with University of Adelaide, Flinders University of SA, University of Sydney, Boston University (USA), McMaster University (Canada) and University of East Anglia (UK).
Qualifications
- Doctor of Philosophy, University of Adelaide
- Bachelor of Medicine, Bachelor of Surgery, University of Adelaide
Keywords
- Aortic valve stenosis
- Biomarkers
- Cardio-oncology
- Cardiomyopathy
- Clinical cardiology
- Heart Failure
- Mitochondria
- Obesity and heart disease
- Oxidative stress
Languages
- English (Fluent)
- Russian (Fluent)
Fields of Research
| Code | Description | Percentage |
|---|---|---|
| 110107 | Metabolic Medicine | 10 |
| 110201 | Cardiology (incl. Cardiovascular Diseases) | 80 |
| 111299 | Oncology and Carcinogenesis not elsewhere classified | 10 |
Professional Experience
UON Appointment
| Title | Organisation / Department |
|---|---|
| Director of Heart Failure | University of Newcastle School of Medicine and Public Health Australia |
Academic appointment
| Dates | Title | Organisation / Department |
|---|---|---|
| 7/12/2017 - | Fellow - Heart Failure Association (FHFA) of the ESC | Heart Failure Association of the European Society of Cardiology France |
| 1/11/2015 - | Fellow - American College of Cardiology (FACC) | American College of Cardiology United States |
| 1/10/2011 - | Fellow - Cardiac Society of Australia and New Zealand (FCSANZ) | Cardiac Society of Australia and NewZealand Australia |
| 17/12/2007 - | Fellow - Royal Australasian College of Physicians (FRACP) | The Royal Australasian College of Physicians Australia |
| 1/7/2012 - 22/5/2017 | NHMRC CJ Martin Fellow | University of Adelaide Australia |
| 1/7/2012 - 15/4/2015 | NHMRC CJ Martin Fellow | Boston University MA Cardiovascular Medicine United States |
| 1/7/2014 - 15/4/2015 | AHA Postdoctoral Fellow | Boston University MA Cardiovascular Medicine United States |
| 1/1/2013 - | Fellow - European Society of Cardiology (FESC) | European Society of Cardiology France |
Professional appointment
| Dates | Title | Organisation / Department |
|---|---|---|
| 1/1/2018 - | Clinical Lead - "Cancer and the Heart" (Cardio-oncology) program | Hunter New England Area Health Service Australia |
| 1/7/2017 - | Clinical Lead - Heart Failure Service | Hunter New England Local Health District NSW Health Cardiovascular Medicine Australia |
| 1/5/2017 - | Clinical Academic Cardiologist | John Hunter Hospital Cardiovascular Medicine Australia |
| 1/2/2008 - 30/6/2012 | Staff Specialist - Cardiology | Queen Elizabeth Hospital Cardiology Department Australia |
| 1/7/2012 - 22/5/2017 | Senior Staff Specialist - Cardiology | Queen Elizabeth Hospital Cardiology Department Australia |
Teaching appointment
| Dates | Title | Organisation / Department |
|---|---|---|
| 1/1/2005 - 31/12/2006 | Chief Medical Resident | Queen Elizabeth Hospital Department of Medicine Australia |
Awards
Award
| Year | Award |
|---|---|
| 2018 |
2018 Ministerial Award for Rising Stars in Cardiovascular Research NSW Health |
Grant Reviews
| Year | Grant | Amount |
|---|---|---|
| 2018 |
Singapore Translational Research Investigaor (STaR) Award C3231 - International Govt - Own Purpose - 3231, C3231 - International Govt - Own Purpose - 3231 |
$7,000,000 |
| 2018 |
Croation Science Foundation (HRZZ) - Project Grant C3232 - International Govt - Other - 3232, C3232 - International Govt - Other - 3232 |
$2,000,000 |
| 2018 |
NHMRC Project Grant Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
| 2018 |
MRC Project Grant - Medical Research Council C3232 - International Govt - Other - 3232, C3232 - International Govt - Other - 3232 |
$0 |
| 2018 |
Heart Foundation Postdoctoral Fellowship Committee Aust Competitive - Non Commonwealth - 1NS, Aust Competitive - Non Commonwealth - 1NS |
$0 |
| 2018 |
American Heart Association - Cardiac Biology Program Peer Review Committee International - Competitive - 3IFA, International - Competitive - 3IFA |
$0 |
| 2017 |
NHMRC Cardiovascular GRP Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
| 2017 |
Heart Foundation Postdoctoral Fellowship Committee Aust Competitive - Non Commonwealth - 1NS, Aust Competitive - Non Commonwealth - 1NS |
$0 |
| 2017 |
American Heart Association - Cardiac Biology Program Peer Review Committee International - Competitive - 3IFA, International - Competitive - 3IFA |
$0 |
| 2016 |
NHMRC Cardiovascular GRP Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
| 2016 |
NHMRC ECF Committee Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
| 2016 |
Rebecca L Cooper Medical Research Foundation Grant Review Committee Grant - Aust Non Government - 3AFG, Grant - Aust Non Government - 3AFG |
$0 |
| 2015 |
ARC Discovery Grants Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
| 2015 |
NHMRC ECF Committee Aust Competitive - Commonwealth - 1CS, Aust Competitive - Commonwealth - 1CS |
$0 |
Publications
For publications that are currently unpublished or in-press, details are shown in italics.
Book (1 outputs)
| Year | Citation | Altmetrics | Link | ||
|---|---|---|---|---|---|
| 2010 |
Chirkov YY, Sverdlov AL, Horowitz JD, Beneficial effects of perhexiline in cardiovascular disease states (2010) © 2010 by Nova Science Publishers, Inc. All rights reserved. Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the ... [more] © 2010 by Nova Science Publishers, Inc. All rights reserved. Perhexiline, 2-(2,2-dicyclohexylethyl)piperidine, was originally developed as a prophylactic anti-anginal drug in the late 1960s. It was initially a popular and effective treatment for angina, having the almost unique property compared to other agents available at that time, of not inducing reductions in blood pressure or heart rate. Despite the initial success, its use diminished markedly due to the occurrence during long-term therapy of poorly understood side effects (neurotoxicity and hepatotoxicity), which later were shown to be associated with high plasma concentrations of perhexiline, occurring in patients with relatively slow hepatic metabolism of the drug. However, therapeutic plasma monitoring and associated dose adjustments have led to perhexiline¿s reintroduction into clinical practice. This new book discusses the benefits of perhexiline in the treatment of cardiovascular disease.
|
Chapter (2 outputs)
| Year | Citation | Altmetrics | Link |
|---|---|---|---|
| 2019 | Sverdlov A, Ngo D, Colucci W, 'Oxidative Stress in Heart Failure', Heart Failure: A Companion to Braunwald's Heart Disease, Elsevier, USA (2019) | ||
| 2016 | Sawyer DB, Sverdlov AL, Colucci WS, 'Oxidative Stress in Heart Failure', Heart Failure A Companion to Braunwald's Heart Disease, Elsevier, Philadelphia 127-139 (2016) |
Journal article (63 outputs)
| Year | Citation | Altmetrics | Link | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020 |
Untaru R, Chen D, Kelly C, May A, Collins NJ, Leitch J, et al., 'Suboptimal Use of Cardioprotective Medications in Patients With a History of Cancer', JACC: CardioOncology, 2 312-315 (2020)
|
||||||||||
| 2020 |
Al-Omary MS, Sugito S, Boyle AJ, Sverdlov AL, Collins NJ, 'Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy.', Hypertension, 75 1397-1408 (2020)
|
||||||||||
| 2020 |
Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al., 'Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.', Eur J Heart Fail, (2020)
|
||||||||||
| 2020 |
Ngo DTM, Williams T, Horder S, Kritharides L, Vardy J, Mandaliya H, et al., 'Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab.', J Clin Med, 9 (2020)
|
||||||||||
| 2020 |
Diaz A, Sverdlov AL, Kelly B, Ngo DTM, Bates N, Garvey G, 'Nexus of cancer and cardiovascular disease for Australia's first peoples', Journal of Global Oncology, 2020 115-119 (2020) [C1]
|
||||||||||
| 2019 |
Murtha L, Morten M, Schuliga M, Mabotuwana N, Hardy S, Waters D, et al., 'The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis', Aging and Disease, 10 419-428 (2019) [C1]
|
||||||||||
| 2019 |
Gopal DM, Ayalon N, Wang Y-C, Siwik D, Sverdlov A, Donohue C, et al., 'Galectin-3 Is Associated With Stage B Metabolic Heart Disease and Pulmonary Hypertension in Young Obese Patients', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 8 (2019) [C1]
|
||||||||||
| 2019 |
Ezad S, Khan AA, Cheema H, Ashraf A, Ngo DTM, Sverdlov AL, Collins NJ, 'Ibrutinib-related atrial fibrillation: A single center Australian experience', Asia-Pacific Journal of Clinical Oncology, 15 e187-e190 (2019) [C1] © 2019 John Wiley & Sons Australia, Ltd Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of ar... [more] © 2019 John Wiley & Sons Australia, Ltd Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of arrhythmia are variable in different studies. The aim of the current analysis was to evaluate the incidence of AF in a single-center cohort of patients. Methods: This analysis was conducted at Hunter New England Local Health District, Australia between April 1, 2015 and June 30, 2017. We included all consecutive patients commenced on ibrutinib for hematological malignancies. Patients with a history of paroxysmal AF were excluded. The primary end point was incidence of AF. Time to diagnosis and management were secondary outcomes of interest. Results: A total of 24 patients (age 73¿±¿9 years, males n¿=¿16 [67%]) were commenced on ibrutinib treatment during the study period with chronic lymphocytic leukemia (n¿=¿21, 88%) as the main indication. During a median follow-up of 12 months, four (17%) patients were diagnosed with AF with increasing age, duration of ibrutinib treatment as associations. The median time to AF diagnosis was 9 (interquartile range [IQR]: 7-18) months. All patients were managed with a rate control strategy with beta blockers as the preferred agents. Three (75%) patients were commenced on anticoagulation for stroke prevention. During a follow-up of 18 (IQR: 17-23) months following AF onset, one patient required hospitalization for AF. There were no bleeding complications reported. Conclusions: In conclusion, this series noted a higher incidence of AF than previously reported. Oncologists and cardiologists need to be aware of the increased risk of AF in patients receiving ibrutinib.
|
||||||||||
| 2019 |
Croft AJ, Ngo DTM, Sverdlov AL, 'Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again', Heart Lung and Circulation, 28 1454-1456 (2019) [C1]
|
||||||||||
| 2019 |
Ngo DTM, Sverdlov AL, Karki S, Macartney-Coxson D, Stubbs RS, Farb MG, et al., 'Oxidative modifications of mitochondrial complex ii are associated with insulin resistance of visceral fat in obesity', American Journal of Physiology - Endocrinology and Metabolism, 316 E168-E177 (2019) [C1] © 2019 the American Physiological Society. Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been ... [more] © 2019 the American Physiological Society. Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been suggested as mechanisms of insulin resistance. The mechanism(s) behind this remains incompletely understood. In this study, we hypothesized that mitochondrial complex II dysfunction plays a role in impaired insulin sensitivity in visceral adipose tissue of subjects with obesity. We obtained subcutaneous and visceral adipose tissue biopsies from 43 subjects with obesity (body mass index = 30 kg/m 2 ) during planned bariatric surgery. Compared with subcutaneous adipose tissue, visceral adipose tissue exhibited decreased complex II activity, which was restored with the reducing agent dithiothreitol (5 mM) (P < 0.01). A biotin switch assay identified that cysteine oxidative posttranslational modifications (OPTM) in complex II subunit A (succinate dehydrogenase A) were increased in visceral vs. subcutaneous fat (P < 0.05). Insulin treatment (100 nM) stimulated complex II activity in subcutaneous fat (P < 0.05). In contrast, insulin treatment of visceral fat led to a decrease in complex II activity (P < 0.01), which was restored with addition of the mitochondria-specific oxidant scavenger mito-TEMPO (10 µ M). In a cohort of 10 subjects with severe obesity, surgical weight loss decreased OPTM and restored complex II activity, exclusively in the visceral depot. Mitochondrial complex II may be an unrecognized and novel mediator of insulin resistance associated with visceral adiposity. The activity of complex II is improved by weight loss, which may contribute to metabolic improvements associated with bariatric surgery.
|
||||||||||
| 2019 |
Luptak I, Qin F, Sverdlov AL, Pimentel DR, Panagia M, Croteau D, et al., 'Energetic dysfunction is mediated by mitochondrial reactive oxygen species and precedes structural remodeling in metabolic heart disease', Antioxidants and Redox Signaling, 31 539-549 (2019) [C1] © Copyright 2019, Mary Ann Liebert, Inc., publishers 2019. Aims: Metabolic syndrome is associated with metabolic heart disease (MHD) that is characterized by left ventricular (LV)... [more] © Copyright 2019, Mary Ann Liebert, Inc., publishers 2019. Aims: Metabolic syndrome is associated with metabolic heart disease (MHD) that is characterized by left ventricular (LV) hypertrophy, interstitial fibrosis, contractile dysfunction, and mitochondrial dysfunction. Overexpression of catalase in mitochondria (transgenic expression of catalase targeted to the mitochondria [mCAT]) prevents the structural and functional features of MHD caused by a high-fat, high-sucrose (HFHS) diet for =4 months. However, it is unclear whether the effect of mCAT is due to prevention of reactive oxygen species (ROS)-mediated cardiac remodeling, a direct effect on mitochondrial function, or both. To address this question, we measured myocardial function and energetics in mice, with or without mCAT, after 1 month of HFHS, before the development of cardiac structural remodeling. Results: HFHS diet for 1 month had no effect on body weight, heart weight, LV structure, myocyte size, or interstitial fibrosis. Isolated cardiac mitochondria from HFHS-fed mice produced 2.2- to 3.8-fold more H2O2, and 16%-29% less adenosine triphosphate (ATP). In isolated beating hearts from HFHS-fed mice, [phosphocreatine (PCr)] and the free energy available for ATP hydrolysis (¿G~ATP) were decreased, and they failed to increase with work demands. Overexpression of mCAT normalized ROS and ATP production in isolated mitochondria, and it corrected myocardial [PCr] and ¿G~ATP in the beating heart. Innovation: This is the first demonstration that in MHD, mitochondrial ROS mediate energetic dysfunction that is sufficient to impair contractile function. Conclusion: ROS produced and acting in the mitochondria impair myocardial energetics, leading to slowed relaxation and decreased contractile reserve. These effects precede structural remodeling and are corrected by mCAT, indicating that ROS-mediated energetic impairment, per se, is sufficient to cause contractile dysfunction in MHD.
|
||||||||||
| 2018 |
Luptak I, Sverdlov AL, Panagia M, Qin F, Pimentel DR, Croteau D, et al., 'Decreased ATP production and myocardial contractile reserve in metabolic heart disease.', Journal of molecular and cellular cardiology, 116 106-114 (2018) [C1]
|
||||||||||
| 2018 |
Efird JT, Jindal C, Kiser AC, Akhter SA, Crane PB, Kypson AP, et al., 'Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents', Journal of International Medical Research, 46 3183-3194 (2018) [C1] © The Author(s) 2018. Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more f... [more] © The Author(s) 2018. Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patients who receive perioperative inotropic therapy (PINOT). Administration of nitrates with antiplatelet agents reduces the conversion rate of cyclic guanosine monophosphate to guanosine monophosphate. This process is associated with increased concentrations of free radicals, catecholamines, and blood plasma volume. We hypothesized that patients undergoing CABG surgery who receive PINOT may be more susceptible to POAF when nitrates are administered with antiplatelet agents. Methods: Clinical records were examined from a prospectively maintained cohort of 4,124 patients undergoing primary isolated CABG surgery to identify POAF-associated factors. Results: POAF risk was increased among patients receiving PINOT, and the greatest effect was observed when nitrates were administered with antiplatelet therapy. Adjustment for comorbidities did not substantively change the study results. Conclusions: Administration of nitrates with certain antiplatelet agents was associated with an increased POAF risk among patients undergoing CABG surgery. Additional studies are needed to determine whether preventive strategies such as administration of antioxidants will reduce this risk.
|
||||||||||
| 2018 |
Al-Omary MS, Khan AA, Davies AJ, Fletcher PJ, Mcivor D, Bastian B, et al., 'Outcomes following heart failure hospitalization in a regional Australian setting between 2005 and 2014.', ESC heart failure, 5 271-278 (2018) [C1]
|
||||||||||
| 2016 |
Amarasekera AT, Sverdlov AL, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients', Diabetes and Metabolism, 42 378-381 (2016) [C1]
|
||||||||||
| 2015 |
Sverdlov AL, Elezaby A, Behring JB, Bachschmid MM, Luptak I, Tu VH, et al., 'High fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to oxidative post-translational modification of mitochondrial complex II', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 78 165-173 (2015) [C1]
|
||||||||||
| 2015 |
Yao C, Behring JB, Shao D, Sverdlov AL, Whelan SA, Elezaby A, et al., 'Overexpression of Catalase Diminishes Oxidative Cysteine Modifications of Cardiac Proteins', PLOS ONE, 10 (2015) [C1]
|
||||||||||
| 2015 |
Horowitz JD, Chong C-R, Ngo DT, Sverdlov AL, 'Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?', JOURNAL OF THORACIC DISEASE, 7 E607-E611 (2015)
|
||||||||||
| 2015 |
Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, et al., 'Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 79 275-283 (2015) [C1]
|
||||||||||
| 2014 |
Procter NEK, Chong C-R, Sverdlov AL, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics', SEMINARS IN THROMBOSIS AND HEMOSTASIS, 40 660-668 (2014)
|
||||||||||
| 2014 |
Chong C-R, Chan WPA, Nguyen TH, Liu S, Procter NEK, Ngo DT, et al., 'Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes', CARDIOVASCULAR DRUGS AND THERAPY, 28 347-360 (2014)
|
||||||||||
| 2014 |
Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al., 'Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis', JOURNAL OF NUCLEAR CARDIOLOGY, 21 925-939 (2014)
|
||||||||||
| 2014 |
Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of the Nitric Oxide System: Are We as Old as Our NO?', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3 (2014)
|
||||||||||
| 2013 |
Chan WPA, Ngo DT, Sverdlov AL, Rajendran S, Stafford I, Heresztyn T, et al., 'Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome', AMERICAN JOURNAL OF MEDICINE, 126 (2013) [C1]
|
||||||||||
| 2013 |
Maher AR, Arif S, Madhani M, Abozguia K, Ahmed I, Fernandez BO, et al., 'Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite', BRITISH JOURNAL OF PHARMACOLOGY, 169 659-670 (2013) [C1]
|
||||||||||
| 2013 |
Sverdlov AL, Chan WPA, Procter NEK, Chirkov YY, Ngo DTM, Horowitz JD, 'Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy', INTERNATIONAL JOURNAL OF CARDIOLOGY, 168 4624-4630 (2013)
|
||||||||||
| 2013 |
Ngo DTM, Horowitz JD, Sverdlov AL, 'Heart Failure A Corin-Deficient State?', HYPERTENSION, 61 284-285 (2013)
|
||||||||||
| 2013 |
Nguyen TH, Neil CJ, Sverdlov AL, Ngo DT, Chan WP, Heresztyn T, et al., 'Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?', CARDIOVASCULAR DRUGS AND THERAPY, 27 541-547 (2013)
|
||||||||||
| 2013 |
Dautov RF, Ngo DTM, Licari G, Liu S, Sverdlov AL, Ritchie RH, et al., 'The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 35 72-78 (2013)
|
||||||||||
| Show 60 more journal articles | |||||||||||
Conference (34 outputs)
| Year | Citation | Altmetrics | Link | ||||
|---|---|---|---|---|---|---|---|
| 2020 | Al-Omary M, Mcgee M, Sugito S, Sverdlov AL, Boyle AJ, 'OUTCOMES OF HEART FAILURE AND ACUTE CORONARY SYNDROME IN INDIGENOUS POPULATION IN A REGIONAL AUSTRALIAN SETTING', JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Chicago, IL (2020) | ||||||
| 2018 |
Chambers J, Elezaby A, Croteau D, Sverdlov A, Liesa M, Shirihai O, et al., 'ABCB10 deletion in cardiomyocytes leads to mitochondrial dysfunction and early death', FREE RADICAL BIOLOGY AND MEDICINE, Chicago, IL (2018)
|
||||||
| 2016 |
Chua SJ, Ajaero C, Assadi-Khansari B, McGavigan A, Horowitz JD, Sverdlov AL, Ngo DTM, 'Galectin 3 is markedly elevated in severe heart failure and predicts improvement in LV volumes post cardiac resynchronisation therapy', EUROPEAN HEART JOURNAL, Rome, ITALY (2016)
|
||||||
| 2014 | Sverdlov AL, Elezaby A, Qin F, Behring JB, Bachschmid MM, Luptak I, et al., 'Oxidative Protein Modifications Mediate Mitochondrial Dysfunction in Metabolic Heart Disease: Correction ex vivo and in vivo', CIRCULATION (2014) | ||||||
| 2014 | Luptak I, Sverdlov AL, Elezaby A, Miller EJ, Pimentel DR, Liesa M, et al., 'Western Diet for One Month Impairs Myocardial Energetics and Both Systolic and Diastolic Pump Function in the Mouse Heart', CIRCULATION (2014) | ||||||
| 2014 | Elezaby A, Sverdlov AL, Tu VH, Qin F, Rimer J, Schaffer JE, et al., 'Metabolic Remodeling in Mice with Cardiomyocyte-Specific Fatty Acid Overload', CIRCULATION (2014) | ||||||
| 2013 | Elezaby A, Sverdlov A, Tu V, Soni K, Liesa M, Liesa M, et al., 'Impairment of the PPARa/PGC1a Axis Compromises Mitochondrial Biogenesis and Function in Hearts With Cardiomyocyte-Specific Fatty Acid Transport Protein 1 (FATP1) Overexpression', CIRCULATION, Dallas, TX (2013) | ||||||
| 2013 |
Amarasekera AT, Sverdlov AL, Roberts MS, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations; independent of vitamin D status', EUROPEAN HEART JOURNAL, Amsterdam, NETHERLANDS (2013)
|
||||||
| Show 31 more conferences | |||||||
Grants and Funding
Summary
| Number of grants | 44 |
|---|---|
| Total funding | $4,192,867 |
Click on a grant title below to expand the full details for that specific grant.
20204 grants / $930,948
Can we treat cancer without breaking the heart? From cardiotoxicity to cardioprotection – reversing the impact of cancer therapies on cardiovascular health for cancer patients. $736,786
Funding body: NSW Ministry of Health
| Funding body | NSW Ministry of Health |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Doctor Anthony Proietto, Conjoint Professor Tom Walley, Professor John Attia, Professor John Wiggers, Associate Professor Doan Ngo, Laureate Professor Rodney Scott, Gemma Figtree, Paul Burridge, Alex Lyon, Wilson Colucci, Daniel Lenihan |
| Scheme | Early-Mid Career Researcher Grant |
| Role | Lead |
| Funding Start | 2020 |
| Funding Finish | 2022 |
| GNo | G1901542 |
| Type Of Funding | C2220 - Aust StateTerritoryLocal - Other |
| Category | 2220 |
| UON | Y |
Improving Outcomes Following Hospitalisation for Heart Failure in Regional and Remote NSW – the BEEM-HF Randomised Controlled Trial.$125,000
Funding body: NSW Ministry of Health
| Funding body | NSW Ministry of Health |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov |
| Scheme | Translational Research Grants Scheme |
| Role | Lead |
| Funding Start | 2020 |
| Funding Finish | 2021 |
| GNo | G2000974 |
| Type Of Funding | C2210 - Aust StateTerritoryLocal - Own Purpose |
| Category | 2210 |
| UON | Y |
Better understanding of real-life incidence and treatment of iron deficiency and its impact on outcomes in heart failure patients in regional and rural Australia$57,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo |
| Scheme | Research Grant |
| Role | Lead |
| Funding Start | 2020 |
| Funding Finish | 2022 |
| GNo | G2000567 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
Preclinical testing of novel therapeutics to prevent chemotherapy-induced cardiotoxicity$12,162
Funding body: John Hunter Hospital Charitable Trust
| Funding body | John Hunter Hospital Charitable Trust |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov |
| Scheme | Research Funding |
| Role | Lead |
| Funding Start | 2020 |
| Funding Finish | 2020 |
| GNo | G2000325 |
| Type Of Funding | C3112 - Aust Not for profit |
| Category | 3112 |
| UON | Y |
20197 grants / $320,229
To further develop and test a new paradigm for the management of changing Heart Failure$99,166
Funding body: Biotronik Australia Pty Ltd
| Funding body | Biotronik Australia Pty Ltd |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Professor Andrew Boyle, Associate Professor Doan Ngo |
| Scheme | Entrepreneurs' Programme: Innovation Connections |
| Role | Lead |
| Funding Start | 2019 |
| Funding Finish | 2019 |
| GNo | G1901143 |
| Type Of Funding | C3111 - Aust For profit |
| Category | 3111 |
| UON | Y |
Point-of-care NTproBNP testing to assist management of heart failure in primary practice$66,000
Funding body: Roche Diagnostics Pty Ltd
| Funding body | Roche Diagnostics Pty Ltd |
|---|---|
| Project Team | A/Prof Aaron Sverdlov, A/Prof Doan Ngo, Prof Andrew Boyle, Dr James Leitch |
| Scheme | Equipment Grant |
| Role | Lead |
| Funding Start | 2019 |
| Funding Finish | 2021 |
| GNo | |
| Type Of Funding | C3111 - Aust For profit |
| Category | 3111 |
| UON | N |
Better understanding of real-life incidence and treatment of iron deficiency and its impact on outcomes in heart failure patients in regional and rural Australia$60,000
Funding body: Vifor Pharma
| Funding body | Vifor Pharma |
|---|---|
| Scheme | Project Grant |
| Role | Lead |
| Funding Start | 2019 |
| Funding Finish | 2021 |
| GNo | |
| Type Of Funding | C3111 - Aust For profit |
| Category | 3111 |
| UON | N |
Better understanding of mechanisms underlying heart failure due to obesity$50,000
Funding body: Royal Australasian College of Physicians
| Funding body | Royal Australasian College of Physicians |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo |
| Scheme | Foundation for High Blood Pressure Research Establishment Fellowship |
| Role | Lead |
| Funding Start | 2019 |
| Funding Finish | 2019 |
| GNo | G1801367 |
| Type Of Funding | C3112 - Aust Not for profit |
| Category | 3112 |
| UON | Y |
Novel discovery of Sirtuin-3 isoforms in human cardiomyocytes$20,063
Funding body: John Hunter Hospital Charitable Trust
| Funding body | John Hunter Hospital Charitable Trust |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Ms Amanda Croft, Associate Professor Doan Ngo |
| Scheme | Research Grant |
| Role | Lead |
| Funding Start | 2019 |
| Funding Finish | 2019 |
| GNo | G1900118 |
| Type Of Funding | C2220 - Aust StateTerritoryLocal - Other |
| Category | 2220 |
| UON | Y |
Assessment of vascular function using novel biomarkers in patients with adult congenital heart disease$20,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Doctor Nicholas Collins, Associate Professor Aaron Sverdlov, Mr Conagh Kelly, Professor Andrew Boyle, Doctor Rachel Wong |
| Scheme | Research Grant |
| Role | Investigator |
| Funding Start | 2019 |
| Funding Finish | 2021 |
| GNo | G2000021 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
Improving management and outcomes for patients with cancer therapy-induced cardiotoxicity$5,000
Funding body: National Heart Foundation of Australia
| Funding body | National Heart Foundation of Australia |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov |
| Scheme | 2018 Ministerial Award for Rising Stars in Cardiovascular Research |
| Role | Lead |
| Funding Start | 2019 |
| Funding Finish | 2019 |
| GNo | G1900528 |
| Type Of Funding | C3112 - Aust Not for profit |
| Category | 3112 |
| UON | Y |
20187 grants / $735,747
Improving Outcomes Following Hospitalisation for Heart Failure in Regional and Remote NSW – the BEEM-HF Trial$479,376
Funding body: NSW Ministry of Health
| Funding body | NSW Ministry of Health |
|---|---|
| Project Team | A/Prof Aaron Sverdlov, Prof Andrew Boyle, Dr James Leitch, Dr Maged William, Prof John Attia, Prof John Wiggers, Ms Dawn McIvor, Mr Lindsay Savage, Ms Julie Rutherford, A/Prof Doan Ngo |
| Scheme | Translational Research Grant Scheme (TRGS) |
| Role | Lead |
| Funding Start | 2018 |
| Funding Finish | 2020 |
| GNo | |
| Type Of Funding | C2220 - Aust StateTerritoryLocal - Other |
| Category | 2220 |
| UON | N |
To develop and test a new paradigm for management of changing Heart Failure disease treatment$99,371
Funding body: Biotronik Australia Pty Ltd
| Funding body | Biotronik Australia Pty Ltd |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor Andrew Boyle |
| Scheme | Entrepreneurs' Programme: Innovation Connections |
| Role | Lead |
| Funding Start | 2018 |
| Funding Finish | 2018 |
| GNo | G1801209 |
| Type Of Funding | C3111 - Aust For profit |
| Category | 3111 |
| UON | Y |
Predicting tOxicity for Myeloma Therapy (PrOMT)$50,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Doctor Anoop Enjeti, Doctor Wojt Janowski, Doctor Chen Chen Jiang, Associate Professor Aaron Sverdlov |
| Scheme | Project Grant |
| Role | Investigator |
| Funding Start | 2018 |
| Funding Finish | 2018 |
| GNo | G1900030 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
Health Economic analyses for BEEM-HF trial$40,000
Funding body: Hunter New England Local Health District
| Funding body | Hunter New England Local Health District |
|---|---|
| Project Team | A/Prof Aaron Sverdlov, A/Prof Andrew Searles |
| Scheme | 2018 HNE MRSP |
| Role | Lead |
| Funding Start | 2018 |
| Funding Finish | 2020 |
| GNo | |
| Type Of Funding | Other Public Sector - Local |
| Category | 2OPL |
| UON | N |
Identification of novel biomarkers to predict early onset chemotherapy-induced cardiovascular toxicities$37,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Associate Professor Doan Ngo, Associate Professor Aaron Sverdlov, Dr Anoop Enjeti, Prof Philip Rowlings, Associate Professor Anthony Proietto |
| Scheme | Project Grant |
| Role | Investigator |
| Funding Start | 2018 |
| Funding Finish | 2018 |
| GNo | G1801448 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
Determining the mechanisms of myocardial infarction induced cardiac fibrosis: what role does fibulin-3 play?$25,000
Funding body: Hunter Medical Research Institute
| Funding body | Hunter Medical Research Institute |
|---|---|
| Project Team | Doctor Lucy Murtha, Professor Andrew Boyle, Associate Professor Doan Ngo, Associate Professor Aaron Sverdlov |
| Scheme | Project Grant |
| Role | Investigator |
| Funding Start | 2018 |
| Funding Finish | 2018 |
| GNo | G1801370 |
| Type Of Funding | C3120 - Aust Philanthropy |
| Category | 3120 |
| UON | Y |
Statistical analyses for BEEM-HF trial$5,000
Funding body: Hunter New England Local Health District
| Funding body | Hunter New England Local Health District |
|---|---|
| Project Team | A/Prof Aaron Sverdlov; CREDITTS group |
| Scheme | HRTC |
| Role | Lead |
| Funding Start | 2018 |
| Funding Finish | 2020 |
| GNo | |
| Type Of Funding | Other Public Sector - Local |
| Category | 2OPL |
| UON | N |
20177 grants / $746,120
Bench-to-bedside approach to improving management and outcomes for patients with heart failure$529,120
Funding body: National Heart Foundation of Australia
| Funding body | National Heart Foundation of Australia |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov |
| Scheme | Future Leader Fellowship |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2021 |
| GNo | G1700785 |
| Type Of Funding | Aust Competitive - Non Commonwealth |
| Category | 1NS |
| UON | Y |
Cardiometabolic research program$100,000
Funding body: Hunter New England Local Health District
| Funding body | Hunter New England Local Health District |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo |
| Scheme | Project Grant |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2017 |
| GNo | G1701207 |
| Type Of Funding | C3112 - Aust Not for profit |
| Category | 3112 |
| UON | Y |
Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000
Funding body: National Heart Foundation of Australia
| Funding body | National Heart Foundation of Australia |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor John Horowitz, AM |
| Scheme | Vanguard Grant |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2017 |
| GNo | G1701324 |
| Type Of Funding | Aust Competitive - Non Commonwealth |
| Category | 1NS |
| UON | Y |
Equipment Grant - Vevo 1100 Imaging System$20,000
Funding body: Faculty of Health and Medicine, University of Newcastle
| Funding body | Faculty of Health and Medicine, University of Newcastle |
|---|---|
| Scheme | Faculty Grant |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2017 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
Assessing the feasibility of angiotensin receptor blocker/neprilysin inhibitor (ARNI) in reducing the progression of aortic valve stenosis$10,000
Funding body: Universtiy of Newcastle
| Funding body | Universtiy of Newcastle |
|---|---|
| Scheme | Linkage Pilot Grant |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2018 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
EMCR EQUIPMENT GRANT$10,000
Funding body: Hunter Medical Research Institute (HMRI)
| Funding body | Hunter Medical Research Institute (HMRI) |
|---|---|
| Scheme | Unknown |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2017 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
Dissecting hypertrophic pathways in obesity-mediated heart failure$2,000
Funding body: Faculty of Health and Medicine Pilot Grant University of Newcastle
| Funding body | Faculty of Health and Medicine Pilot Grant University of Newcastle |
|---|---|
| Scheme | UON Faculty of Health and Medicine Pilot Grant |
| Role | Lead |
| Funding Start | 2017 |
| Funding Finish | 2017 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
20165 grants / $224,516
Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity?$75,000
Funding body: National Heart Foundation of Australia
| Funding body | National Heart Foundation of Australia |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo, Professor John Horowitz |
| Scheme | Vanguard Grant |
| Role | Lead |
| Funding Start | 2016 |
| Funding Finish | 2018 |
| GNo | |
| Type Of Funding | Aust Competitive - Non Commonwealth |
| Category | 1NS |
| UON | N |
Regulators of the novel anti-angiogenic isoform: VEGF-A165b in obesity$60,000
Funding body: Diabetes Australia
| Funding body | Diabetes Australia |
|---|---|
| Project Team | Associate Professor Doan Ngo (Lead), Associate Professor Aaron Sverdlov |
| Scheme | Research Grant |
| Role | Investigator |
| Funding Start | 2016 |
| Funding Finish | 2017 |
| GNo | |
| Type Of Funding | Aust Competitive - Non Commonwealth |
| Category | 1NS |
| UON | N |
Early detection of chemotherapy-induced cardiomyopathy$50,000
Funding body: Royal Australasian College of Physicians
| Funding body | Royal Australasian College of Physicians |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo |
| Scheme | Research Establishment Award |
| Role | Lead |
| Funding Start | 2016 |
| Funding Finish | 2018 |
| GNo | |
| Type Of Funding | Grant - Aust Non Government |
| Category | 3AFG |
| UON | N |
Metabolic heart disease: markers and mechanisms$25,000
Funding body: Rebecca L Cooper Medical Research Foundation Ltd
| Funding body | Rebecca L Cooper Medical Research Foundation Ltd |
|---|---|
| Project Team | Associate Professor Aaron Sverdlov, Associate Professor Doan Ngo |
| Scheme | Research Grant |
| Role | Lead |
| Funding Start | 2016 |
| Funding Finish | 2017 |
| GNo | G1701494 |
| Type Of Funding | C3112 - Aust Not for profit |
| Category | 3112 |
| UON | Y |
Are mitochondrial reactive oxygen species key mediators of metabolic syndrome-induced heart disease$14,516
Funding body: The University of Adelaide
| Funding body | The University of Adelaide |
|---|---|
| Scheme | Shared |
| Role | Lead |
| Funding Start | 2016 |
| Funding Finish | 2016 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
20152 grants / $470,000
Oxidative posttranslational modifications of mitochondrial complex II in metabolic heart disease$450,000
Funding body: The University of Sydney
| Funding body | The University of Sydney |
|---|---|
| Scheme | - |
| Role | Lead |
| Funding Start | 2015 |
| Funding Finish | 2017 |
| GNo | |
| Type Of Funding | Grant - Aust Non Government |
| Category | 3AFG |
| UON | N |
Start up grant$20,000
Funding body: University of Adelaide
| Funding body | University of Adelaide |
|---|---|
| Scheme | Unknown |
| Role | Lead |
| Funding Start | 2015 |
| Funding Finish | 2015 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
20141 grants / $130,000
Oxidative posttranslational modifications of mitochondrial complex II in metabolic heart disease$130,000
Funding body: American Heart Association
| Funding body | American Heart Association |
|---|---|
| Scheme | Postdoctoral Fellowship |
| Role | Lead |
| Funding Start | 2014 |
| Funding Finish | 2015 |
| GNo | |
| Type Of Funding | International - Competitive |
| Category | 3IFA |
| UON | N |
20131 grants / $3,100
Keystone Symposium Travel Grant$3,100
Funding body: The University of Adelaide
| Funding body | The University of Adelaide |
|---|---|
| Scheme | Travel Grant |
| Role | Lead |
| Funding Start | 2013 |
| Funding Finish | 2013 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
20125 grants / $481,107
Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$435,257
Funding body: NHMRC (National Health & Medical Research Council)
| Funding body | NHMRC (National Health & Medical Research Council) |
|---|---|
| Project Team | A/Prof Aaron Sverdlov |
| Scheme | Early Career Fellowships |
| Role | Lead |
| Funding Start | 2012 |
| Funding Finish | 2017 |
| GNo | |
| Type Of Funding | Aust Competitive - Commonwealth |
| Category | 1CS |
| UON | N |
Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$20,000
Funding body: Royal Australasian College of Physicians
| Funding body | Royal Australasian College of Physicians |
|---|---|
| Scheme | Margorie Hooper Fellowship |
| Role | Lead |
| Funding Start | 2012 |
| Funding Finish | 2013 |
| GNo | |
| Type Of Funding | Grant - Aust Non Government |
| Category | 3AFG |
| UON | N |
Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$15,000
Funding body: Medtronic
| Funding body | Medtronic |
|---|---|
| Scheme | Postdoctoral project funding |
| Role | Lead |
| Funding Start | 2012 |
| Funding Finish | 2017 |
| GNo | |
| Type Of Funding | Donation - Aust Non Government |
| Category | 3AFD |
| UON | N |
Lipotoxicity, mitochondrial dysfunction and the pathogenesis of heart failure$10,000
Funding body: Boston Scientific
| Funding body | Boston Scientific |
|---|---|
| Scheme | Postdoctoral project funding |
| Role | Lead |
| Funding Start | 2012 |
| Funding Finish | 2017 |
| GNo | |
| Type Of Funding | Donation - Aust Non Government |
| Category | 3AFD |
| UON | N |
Travel Award$850
Funding body: Seahorse Bioscience
| Funding body | Seahorse Bioscience |
|---|---|
| Scheme | Travel Award |
| Role | Lead |
| Funding Start | 2012 |
| Funding Finish | 2012 |
| GNo | |
| Type Of Funding | International - Non Competitive |
| Category | 3IFB |
| UON | N |
20092 grants / $4,500
AHA 2009 Traveling Fellowship$3,000
Funding body: Cardiac Society of Australia and NewZealand
| Funding body | Cardiac Society of Australia and NewZealand |
|---|---|
| Scheme | Travelling Fellowship |
| Role | Lead |
| Funding Start | 2009 |
| Funding Finish | 2009 |
| GNo | |
| Type Of Funding | Grant - Aust Non Government |
| Category | 3AFG |
| UON | N |
Small Grant$1,500
Funding body: Heart Foundation
| Funding body | Heart Foundation |
|---|---|
| Scheme | E O Myers Trust Fund Grant |
| Role | Lead |
| Funding Start | 2009 |
| Funding Finish | 2009 |
| GNo | |
| Type Of Funding | Aust Competitive - Non Commonwealth |
| Category | 1NS |
| UON | N |
20082 grants / $61,600
Pathogenesis of aortic valve sclerosis$55,000
Funding body: CVL - Pfiser
| Funding body | CVL - Pfiser |
|---|---|
| Scheme | Unknown |
| Role | Lead |
| Funding Start | 2008 |
| Funding Finish | 2008 |
| GNo | |
| Type Of Funding | Grant - Aust Non Government |
| Category | 3AFG |
| UON | N |
Equipment grant$6,600
Funding body: Heart Foundation
| Funding body | Heart Foundation |
|---|---|
| Scheme | J Fund Grant |
| Role | Lead |
| Funding Start | 2008 |
| Funding Finish | 2008 |
| GNo | |
| Type Of Funding | Aust Competitive - Non Commonwealth |
| Category | 1NS |
| UON | N |
20051 grants / $85,000
Pathogenesis of aortic valve stenosis$85,000
Funding body: The University of Adelaide
| Funding body | The University of Adelaide |
|---|---|
| Scheme | Faculty of Health Sciences Divisional PhD Scholarship |
| Role | Lead |
| Funding Start | 2005 |
| Funding Finish | 2010 |
| GNo | |
| Type Of Funding | Internal |
| Category | INTE |
| UON | N |
Research Supervision
Number of supervisions
Current Supervision
| Commenced | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2020 | PhD | Can Improving Redox State in Obesity Protect the Heart from Failure and the Gut from Cancer? | PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle | Principal Supervisor |
| 2020 | PhD | Improving Cardiovascular Outcomes for Cancer Patients and Survivors: Focus on Novel Biomarkers for Risk Stratification | PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
| 2019 | PhD | Pathophysiology of Obesity-Induced Cardiometabolic Dysfunction: The Link With Colorectal Cancer | PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
| 2019 | PhD | Improving Outcomes following Hospitalisation for Heart Failure in Regional and Remote NSW-the BEEM-HF Study | PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle | Principal Supervisor |
| 2018 | PhD | Heart Failure Outcomes in Hunter New England Area | PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
| 2018 | PhD | Early Detection of Cardiotoxicity from Chemotherapy | PhD (Pharmacy), Faculty of Health and Medicine, The University of Newcastle | Co-Supervisor |
| 2017 | PhD | Establishment and Evaluation of a nurse-led cardio-oncology Unit | Nursing, Flinders University | Co-Supervisor |
| 2017 | Post-Doctoral Fellowship | Heart Failure pathophysiology and novel biomarkers | Medical Science, University of Adelaide | Co-Supervisor |
| 2016 | PhD | The Use of N-acetylcysteine and Ramipril to improve clinical outcomes in Tako Tsubo Cardiomyopathy | Medical Science, University of Adelaide | Co-Supervisor |
Past Supervision
| Year | Level of Study | Research Title | Program | Supervisor Type |
|---|---|---|---|---|
| 2018 | Post-Doctoral Fellowship | Beetroot supplementation and exercise tolerance: another way to boost physical activity to combat obesity? | Medical Science, School of Medicine & Public Health, Faculty of Health & Medicine, University of Newcastle | Australia | Principal Supervisor |
| 2018 | Honours | Heart failure: novel biomarkers | Medical Science, University of Adelaide | Co-Supervisor |
Research Opportunities
Early Detection of Chemotherapy-induced Cardiotoxicity
Contact
Associate Professor Aaron Sverdlov
University of Newcastle
School of Medicine and Public Health
aaron.sverdlov@newcastle.edu.au
News
Hearty success in NSW Medical Research Cardiovascular grants
May 7, 2020
Heart failure researcher named 2018 rising star
November 7, 2018
Newcastle researchers awarded $750,000 to help heart health
December 11, 2017
Associate Professor Aaron Sverdlov
Position
Director of Heart Failure
Cardio-Metabolic and Heart Failure Groups
School of Medicine and Public Health
Faculty of Health and Medicine
Contact Details
| aaron.sverdlov@newcastle.edu.au | |
| Phone | (02) 4042 0725 |
| Links |
Research Networks Research Networks Research Networks |
NEWS • May 07.2020
Hearty success in NSW Medical Research Cardiovascular grants
Heart disease kills one person every 12 minutes in Australia, and is still the leading cause of death globally. Despite enormous improvements in health outcomes over the years, heart disease is still one of the biggest health burdens on our economy.
NEWS • Dec 11.2017
Newcastle researchers awarded $750,000 to help heart health
Six Hunter researchers have secured $750,000 in Heart Foundation funding to investigate heart disease, Australia’s leading cause of death.
